Skip to main content

Table 4 Correlation analysis of YAP1 protein expression levels with the clinical parameters in Indian breast cancer patients

From: Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients

Characteristic Total (N) YAP1 absent YAP1 present p value
Age (years)
≤50 78 (56.93) 64 (82.05) 14 (17.95) 0.3
>50 59 (43.07) 44 (74.58) 15 (25.42)  
Age at menarche
≤12 26 (18.98) 23 (88.46) 3 (11.54) 0.258
>12 111 (81.02) 85 (76.58) 26 (23.42)  
Menopausal status
Premenopausal 40 (29.20) 32 (80) 8 (20) 1
Postmenopausal 97 (70.80) 76 (78.35) 21 (21.65)  
Age at menopause
≤45 33 (34.02) 28 (84.85) 5 (15.15) 0.309
>45 64 (65.98) 48 (75) 16 (25)  
ER status
Positive 81 (59.12) 58 (71.60) 23 (28.4) 0.018
Negative 56 (40.88) 50 (89.29) 6 (10.71)  
PR status
Positive 47 (34.31) 38 (80.85) 9 (19.15) 0.826
Negative 90 (65.69) 70 (77.78) 20 (22.22)  
Her2 status
Positive 66 (48.18) 52 (78.79) 14 (21.21) 1
Negative 71 (51.82) 56 (78.87) 15 (21.13)  
Molecular subtypes of breast cancer
Luminal A 46 (33.58) 33 (71.74) 13 (28.26) 0.146
Luminal B 38 (27.74) 28 (73.68) 10 (26.32)  
Her2-enriched 28 (20.44) 24 (85.71) 4 (14.29)  
TNBC 25 (18.25) 23 (92) 2 (8)  
Tumor size
≤5 55 (40.15) 47 (85.45) 8 (14.55) 0.139
>5 82 (59.85) 61 (74.39) 21 (25.61)  
Lymph node status
Positive 99 (72.26) 77 (77.78) 22 (22.22) 0.816
Negative 38 (27.74) 31 (81.58) 7 (18.42)  
Clinical stage     
I+II 45(32.85) 38 (84.44) 7 (15.56) 0.373
III+IV 92(67.15) 70 (76.09) 22 (23.91)  
Histological grade
I+II 95 (69.34) 76 (80) 19 (20) 0.653
III 42 (30.66) 32 (76.19) 10 (23.81)  
  1. p value (Fisher’s Exact Test), Bonferroni significance level ≤ 0.005